In parallel, losartan shifts the immune landscape towards an immunostimulatory state, increasing CD8+ T cells, NK cells, and activated dendritic cells, while limiting Tregs and MDSCs, and may further sensitize tumor cells by suppressing IGF-1-mediated survival pathways. This evidence concerns the gene CD8A and neoplasm.